Clinical reference Biomarker Directory
Back to directory

Gastrin-releasing peptide

Emerging

ProGRP is a specific small cell lung cancer marker, often used alongside NSE for improved diagnostic accuracy.

Also known as ProGRP pro-gastrin-releasing peptide
In plain language

ProGRP is a blood marker most often used, together with NSE, to help diagnose and monitor small cell lung cancer, a fast-growing lung cancer type. It has a practical lab advantage over NSE since it isn't as easily thrown off by how the blood sample was handled.

Biomarker & context

Gastrin-releasing peptide precursor (ProGRP) is a neuroendocrine peptide marker most closely associated with small cell lung cancer (SCLC), connecting to the neuron-specific enolase discussion much earlier in this biomarker set.

What it indicates

Elevated ProGRP supports SCLC diagnosis and monitoring; it's often considered the more specific of the two main SCLC markers, with NSE and ProGRP frequently ordered together to improve diagnostic and monitoring accuracy for this aggressive cancer type.

Diagnosis & clinical testing

Measured via serum immunoassay; ProGRP has an advantage over NSE in that it's less affected by sample hemolysis (a technical artifact that can falsely elevate NSE), making it a more reliable marker in practice for some laboratories.

Guiding treatment

Serial ProGRP, alongside NSE, is used to track treatment response and monitor for recurrence in SCLC, given the cancer's typically aggressive course and need for close surveillance.

Clinical significance

Less affected by sample hemolysis than NSE, giving it a practical laboratory reliability advantage.

References
  1. General oncology reference literature on ProGRP and NSE as combined small cell lung cancer biomarkers.